Statins used to treat hyperlipidemia also exhibit immunomodulatory properties. What is still unclear and a matter of debate, however, is whether these properties are of benefi t or are deleterious in collagen type II-induced arthritis (CIA).
Statins used to treat hyperlipidemia also exhibit immunomodulatory properties. What is still unclear and a matter of debate, however, is whether these properties are of benefi t or are deleterious in collagen type II-induced arthritis (CIA).
We read with great interest Vandebriel and colleagues' article about the role of statins in the induction of CIA [1] . According to the authors' conclusion, statins accelerate the onset of CIA in mice. In their study, as previously reported [2] , oral atorvastatin and pravastatin had no eff ect on the arthritis score after CIA induction. Nonetheless, the oral route might be ineff ective due to the signifi cant hepatic fi rst-pass metabolism of statins.
We performed a study that assessed the eff ects of simvastatin administrated by subcutaneous and intraperi to neal routes in CIA as previously reported [3] . Of the 60 rats included, 50 developed CIA (83.3%) and were treated by daily intra peritoneal simvastatin (n = 5), subcutaneous simvastatin (n = 9), diluted subcutaneous simvastatin (n = 9), sub cutaneous saline (n = 9), and intraperitoneal saline (n = 9) for a total of 15 days. Nine rats received no treatment. A total score was calculated by grading each joint of the four limbs using a scale of 0 to 3 (0 = normal, 1 = erythema, 2 = erythema + swelling, and 3 = loss of function).
At baseline, no diff erence was noted in the arthritis score or weight between groups. We observed a significant weight decrease in each treatment group but no diff erence in weight loss between groups. After adjusting for weight, there was a signifi cant diff erence in arthritis scores between intraperitoneal simvastatin and the other groups, with signifi cantly lower arthritis scores obtained in the intraperitoneal simvastatin group (Figure 1) . Th e diff erence of the arthritis score between subcutaneous simvastatin and intraperitoneal simvastatin was significant (P = 0.002) (intraperitoneal: 3.67 ± 1.32 at baseline and 4.89 ± 1.69 after 15 days vs. subcutaneous: 4.20 ± 0.84 at baseline and 7.40 ± 1.34 after 15 days). Diff erences in arthritis scores between the other groups, except for the simvastatin group, were not signifi cant (Figure 1 ). Th ese results obtained using linear mixedmodels analysis were similar to those obtained when using PROAST, a general program for dose-response modeling, as in Vandebriel and colleagues' article.
In the intraperitoneal simvastatin group, there was a limitation in the progression of the arthritis score in rats, whereas no eff ect was noted in the subcutaneous simvastatin group.
Statins may therefore be a therapeutic option in CIA, provided that the substantial eff ects of hepatic fi rst-pass metabolism are avoided. For CIA treatment, it might thus be interesting to administer transdermal statin patches that enhance diff usion, which have been reported to increase bone formation in rats [4] . Perhaps these patches could also be a therapeutic option in human rheumatoid arthritis.
